preloader

Bio Details

Tony Rosenberg

Tony Rosenberg is Chairman of the Board at Cullinan and an Executive Partner at MPM Capital.

Previously, Tony was Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role, he oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics.

Tony brings more than 30 years of biotech operations and strategic management experience to Cullinan. He joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group.

Tony has a B.S. in Biological Sciences from the University of Leicester and a M.S. in Physiology from the University of London.

Tony currently serves on the Board of Directors of argenx, iOmx Therapeutics, Radius and TriNetX.